Nabriva Therapeutics plc provided revenue guidance for the fourth quarter of 2021. For the period, The company anticipates reporting that total revenue to grow at a mid-to-high single digit percentage as compare to third quarter of 2021's reported total revenue of $8.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3 | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- NBRVF Stock
- News Nabriva Therapeutics plc
- Nabriva Therapeutics plc Provides revenue Guidance for the Fourth Quarter of 2021